Get the Stockscreener App
2.45
2.08%
0.05
Annexon Inc stock is traded at $2.45, with a volume of 871.73K.
It is up +2.08% in the last 24 hours and down -0.81% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$2.40
Open:
$2.35
24h Volume:
871.73K
Relative Volume:
0.59
Market Cap:
$268.80M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.3842
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
-2.39%
1M Performance:
-0.81%
6M Performance:
-36.20%
1Y Performance:
-59.84%
1-Day Range:
$2.2901
$2.47
1-Week Range:
$2.2901
$2.74
52-Week Range:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.45 | 263.31M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
How Annexon Inc. stock performs during market volatilityFree Weekly Return Pick Forecast Reports - Newser
Signal strength of Annexon Inc. stock in tech scannersPortfolio Review Summary with Five-Year Outlook - Newser
How to forecast Annexon Inc. trends using time seriesInsider Strategy for High Conviction Picks - Newser
What are analysts’ price targets for Annexon Inc. in the next 12 monthsAdvanced Screener Data Feed To Watch Now - jammulinksnews.com
Carson William H. buys Annexon (ANNX) shares worth $9,999 - Investing.com
Leading vs lagging indicators on Annexon Inc. performanceProven Trading System with Consistent Gains - Newser
Momentum divergence signals in Annexon Inc. chartFree High Win Rate Trading Opportunities - Newser
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Detecting price anomalies in Annexon Inc. with AIMachine Learning Stock Price Forecast Tool - Newser
Trend analysis for Annexon Inc. this weekSecure Capital Picks With Upside Potential Tracked - metal.it
What makes Annexon Inc. stock attractive to long term investorsRisk-Managed Trade Alerts for Consistency - Newser
Is Annexon Inc. a Top Dividend Stock to Watch in 2025Pattern Breakout Tracker with Screener Tools - Newser
Is Annexon Inc. stock a growth or value playYearly Trend Summary and Opportunity Breakdown - Newser
Technical Heatmap Flags Annexon Inc. for WatchProfit Focused Stock Screener Results Released - beatles.ru
Is Annexon Inc. a growth stock or a value stockNavigate market shifts with confidence - jammulinksnews.com
What markets is CYCC expanding into Is Annexon Inc. stock a good long term investment optionHigh-profit stock alerts - jammulinksnews.com
What are the technical indicators suggesting about Annexon Inc.Achieve rapid wealth accumulation with smart picks - jammulinksnews.com
How Interest Rate Changes Impact Annexon Inc. Stock PerformanceDouble Profit With Half Risk - Newser
Annexon Inc. Stock Analysis and ForecastOutperformance with explosive growth - PrintWeekIndia
Why Annexon Inc. stock attracts strong analyst attentionProven Trading Plan - Newser
Annexon Announces Completion of Enrollment in Pivotal Phase - GlobeNewswire
Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy - Ophthalmology Times
Annexon completes enrollment in Phase 3 ARCHER II trial - TipRanks
Annexon Announces Completion of Enrollment in Pivotal Phase 3 AR - GuruFocus
Annexon (ANNX) Completes Enrollment for Phase 3 Trial of Vonapru - GuruFocus
Annexon completes enrollment for phase 3 dry AMD therapy trial By Investing.com - Investing.com Canada
Annexon completes enrollment for phase 3 dry AMD therapy trial - Investing.com Australia
Annexon, Inc. Completes Enrollment of Phase 3 ARCHER II Trial for Vonaprument, Targeting Vision Preservation in Dry AMD with Geographic Atrophy - Quiver Quantitative
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - Yahoo Finance
What analysts say about Annexon Inc. stockBreakout portfolio performance - Autocar Professional
Is Annexon Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
What drives Annexon Inc. stock priceRapidly expanding wealth - jammulinksnews.com
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):